Nav: Home

Advances in the study of drugs to combat cognitive impairment in schizophrenia

January 15, 2019

Schizophrenia is a serious, chronic mental disorder involving a series of symptoms. It is one of the leading causes of disability worldwide. Various symptoms of this disorder, such as delusions and hallucinations, have been shown to be very adequately treated by means of antipsychotics, and its symptomatology can be improved. Yet patients experience many difficulties on a social and functional level, in other words, "they have severe problems in carrying out everyday life activities ranging from personal hygiene or managing their finances to maintaining a stable social network, having a partner or holding down a job. And there is no treatment for this", explained Arantzazu Zabala, a Doctor in Psychology specialising in neuropsychology.

Since the year 2000, explained Zabala, one of the authors of the work, "it has emerged that it is the cognitive impairments that correlate most with functional deficits, and since then, to combat these deficits, the scientific community has been developing a broad range of interventions, including cognitive enhancers. These are drugs which when added to the routine, antipsychotic treatment, could reverse or, to a certain extent, reduce the cognitive impairments displayed by patients".

Methodological improvements in the interests of progress

Nine clinical trials from across the world were analysed in a study conducted by researchers from the UPV/EHU, the University of La Rioja, the BioCruces Health Research Institute and Cibersam (Centre for Biomedical Research into Mental Health). The trials involved patients with schizophrenia and used three acetylcholinesterase inhibitors (deonepezil, galantamine and rivastignine)that are very effective in improving the cognitive impairments of patients with Alzheimer's. As the researcher explained, "right now there is insufficient evidence to be able to recommend acetylcholinesterase inhibitors as a cognitive enhancer for patients with schizophrenia". In fact, numerous limitations in the nine trials studied have emerged in this meta-analysis, and various improvements that need to be applied to studies of this type have been proposed.

Doctor Zabala is nevertheless optimistic: "Much work remains to be done, but it's heading in the right direction." The researcher insists that the trials analysed "are original pieces of work, are among the first ones, but right now the therapeutic targets have expanded greatly. Our work draws attention to the need for studies that will offer sufficient methodological quality to be able to guarantee the effectiveness of the compounds". In this respect, the research conducted at the UPV/EHU proposes a series of improvements in studies of this type, which the scientific community should bear in mind "so that in addition to demonstrating the effectiveness of a drug on the patient's functionality, aspects such as the safety and tolerance of it are also studied," concluded Zabala.
-end-
Additional information

The research was carried out by lecturers and researchers in the field of Psychiatry in the Department of Neurosciences and the Department of Preventive Medicine and Public Health of the Faculty of Medicine and Nursing of the UPV/EHU, in collaboration with researchers from the International University of La Rioja. Various researchers who are authors of this work participate in CIBERSAM (Centre for Biomedical Research into Mental Health) and belong to the BioCruces Health Research Institute.

Bibliographical reference

Borja Santos, Eduardo González-Fraile, Arantzazu Zabala, Virginia Guillén, José Ramón Rueda, Javier Ballesteros

Cognitive improvement of acetylcholinesterase inhibitors in schizophrenia

Journal of Psychopharmacology (2018)

DOI: 10.1177/0269881118805496

University of the Basque Country

Related Schizophrenia Articles:

Schizophrenia: When the thalamus misleads the ear
Scientists at the University of Geneva (UNIGE) and the Synapsy National Centre of Competence in Research (NCCR) have succeeded in linking the onset of auditory hallucinations - one of the most common symptoms of schizophrenia - with the abnormal development of certain substructures of a region deep in the brain called the thalamus.
Unlocking schizophrenia
New research, led by Prof. LIU Bing and Prof. JIANG Tianzi from the Institute of Automation of the Chinese Academy of Sciences and their collaborators have recently developed a novel imaging marker that may help in the personalized medicine of psychiatric disorders.
Researchers discover second type of schizophrenia
In a study of more than 300 patients from three continents, over one third had brains that looked similar to healthy people.
New clues into the genetic origins of schizophrenia
The first genetic analysis of schizophrenia in an ancestral African population, the South African Xhosa, appears in the Jan.
Dietary supplement may help with schizophrenia
A dietary supplement, sarcosine, may help with schizophrenia as part of a holistic approach complementing antipsychotic medication, according to a UCL researcher.
Schizophrenia: Adolescence is the game-changer
Schizophrenia may be related to the deletion syndrome. However, not everyone who has the syndrome necessarily develops psychotic symptoms.
Study suggests overdiagnosis of schizophrenia
In a small study of patients referred to the Johns Hopkins Early Psychosis Intervention Clinic (EPIC), Johns Hopkins Medicine researchers report that about half the people referred to the clinic with a schizophrenia diagnosis didn't actually have schizophrenia.
The ways of wisdom in schizophrenia
Researchers at UC San Diego School of Medicine report that persons with schizophrenia scored lower on a wisdom assessment than non-psychiatric comparison participants, but that there was considerable variability in levels of wisdom, and those with higher scores displayed fewer psychotic symptoms.
Recognizing the uniqueness of different individuals with schizophrenia
Individuals diagnosed with schizophrenia differ greatly from one another. Researchers from Radboud university medical center, along with colleagues from England and Norway, have demonstrated that very few identical brain differences are shared amongst different patients.
Resynchronizing neurons to erase schizophrenia
Today, a decisive step in understanding schizophrenia has been taken.
More Schizophrenia News and Schizophrenia Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: The Power Of Spaces
How do spaces shape the human experience? In what ways do our rooms, homes, and buildings give us meaning and purpose? This hour, TED speakers explore the power of the spaces we make and inhabit. Guests include architect Michael Murphy, musician David Byrne, artist Es Devlin, and architect Siamak Hariri.
Now Playing: Science for the People

#576 Science Communication in Creative Places
When you think of science communication, you might think of TED talks or museum talks or video talks, or... people giving lectures. It's a lot of people talking. But there's more to sci comm than that. This week host Bethany Brookshire talks to three people who have looked at science communication in places you might not expect it. We'll speak with Mauna Dasari, a graduate student at Notre Dame, about making mammals into a March Madness match. We'll talk with Sarah Garner, director of the Pathologists Assistant Program at Tulane University School of Medicine, who takes pathology instruction out of...
Now Playing: Radiolab

Kittens Kick The Giggly Blue Robot All Summer
With the recent passing of Ruth Bader Ginsburg, there's been a lot of debate about how much power the Supreme Court should really have. We think of the Supreme Court justices as all-powerful beings, issuing momentous rulings from on high. But they haven't always been so, you know, supreme. On this episode, we go all the way back to the case that, in a lot of ways, started it all.  Support Radiolab by becoming a member today at Radiolab.org/donate.